Returns
NAV and returns as at 20 Aug 2026
Lumpsum · point to point
1W
-0.58%
1M
+2.64%
3M
+7.64%
6M
+20.56%
YTD
+17.17%
1Y
+15.36%
2Y CAGR
+11.35%
3Y CAGR
+22.26%
5Y CAGR
—
10Y CAGR
—
SIP · XIRR on monthly instalments
6M SIP
+54.93%
1Y SIP
+28.6%
2Y SIP
+16.13%
3Y SIP
+18.58%
5Y SIP
—
10Y SIP
—
Full history SIP
+18.58%
Periods up to one year are absolute; longer periods are annualised (CAGR). SIP figures are the XIRR of a fixed monthly instalment over the same window. — means this scheme’s NAV history does not cover that period — across all 1648 schemes, 68% have a 3-year figure, 48.8% a 5-year one, and 32.7% a 10-year one.
Top holdings
as at 31 Jul 2026 · source: AMC monthly portfolio disclosure
Sun Pharmaceutical Industries Ltd.Pharmaceuticals & Biotechnology
10.69%
Divi's Laboratories Ltd.Pharmaceuticals & Biotechnology
9.47%
Torrent Pharmaceuticals Ltd.Pharmaceuticals & Biotechnology
6.89%
Apollo Hospitals Enterprise Ltd.Healthcare Services
6.62%
Neuland Laboratories Ltd.Pharmaceuticals & Biotechnology
5.57%
Navin Fluorine International Ltd.Chemicals & Petrochemicals
5.2%
Aurobindo Pharma Ltd.Pharmaceuticals & Biotechnology
5.02%
Zydus Lifesciences Ltd.Pharmaceuticals & Biotechnology
4.9%
Aster DM Quality Care Ltd.Healthcare Services
4.67%
Fortis Healthcare Ltd.Healthcare Services
4.16%
Top 10 63.19%Securities 22Securities total 96.91%Cash & equivalents 3.07%
The ten largest securities by weight, out of 22 disclosed. Weight is percent of net assets as filed. Cash-equivalent lines (TREPS, reverse repo, net receivables, margin) and derivative legs are counted in the chips above but not ranked among securities, because a short futures leg is filed as a negative weight and sorting it alongside a shareholding describes no portfolio. A portfolio is a point-in-time filing and changes every month.
Risk
Volatility · annualised · 3Y
15.37%
Volatility is the annualised standard deviation of daily NAV moves over the last three years; max drawdown is the deepest peak-to-trough fall in that same window. Where a scheme has less than three years of NAV, the window is what it actually has and is labelled as such — never as three years. Sharpe is as disclosed in the scheme key-ratio feed (as at 24 July 2026).
Beta and alpha are not shown. No benchmark series in the source.
Cost
Expense ratio1.42%
Category average1.73%
Exit load1%
52W high / low₹37.8539 / ₹29.6241
Expense ratio 1.42% vs a category average of 1.73% — 0.31 percentage points lower. Among Sectoral/ Thematic schemes disclosing an expense ratio it is 128th of 166, cheapest first.
Expense ratio and category average are as disclosed against this scheme in the source; 78.5% of schemes here carry one. The ratio is charged inside the NAV, so every return on this page is already net of it.
Scheme facts
SEBI sub-category
Sectoral/ Thematic
Plan / option
Direct Growth
Benchmark
BSE Health Care - TRI
Fund manager
Sudhanshu Asthana
Launched
08 Feb 2019
NAV history here
3.0y
ISIN
INF397L01LK4
AMFI scheme code
152024
SEBI riskometer
Very High
Exit load
1%
Lock-in
None
Minimum lumpsum
₹5,000
Exit load, as disclosed: Nil upto 12% of units and 1% for remaining units on or before 90D · Nil after 90D
Not shown on this page, and why
Star rating — GFS is an AMFI-registered distributor (ARN-169480), not a SEBI-registered investment adviser. It does not rate schemes.
Scheme AUM — Scheme-level AUM is not in the source; only AMC-total AUM, which is a different number.
Minimum SIP — Not present in the source.
Beta and alpha — No benchmark series in the source.